Scopus
YÖKSİS Eşleşti
The relationship between serum clozapine concentrations and hematological parameters by a validated mass spectrometric method
Journal of Pharmaceutical and Biomedical Analysis · Şubat 2020
YÖKSİS Kayıtları
The relationship between serum clozapine concentrations and hematological parameters by a validated mass spectrometric method
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS · 2020 SCI-Expanded
PROFESÖR ALİ ÜNLÜ →
The relationship between serum clozapine concentrations andhematological parameters by a validated mass spectrometric method
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS · 2020 SCI-Expanded
DOÇENT GÜLSÜM ABUŞOĞLU →
The relationship between serum clozapine concentrations and hematological parameters by a validated mass spectrometric method
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS · 2020 SCI-Expanded
PROFESÖR MEMDUHA AYDIN →
The relationship between serum clozapine concentrations and hematological parameters by a validated mass spectrometric method
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS · 2020 SCI-Expanded
PROFESÖR ABDULLAH SİVRİKAYA →
The relationship between serum clozapine concentrations andhematological parameters by a validated mass spectrometric method
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS · 2020 SCI-Expanded
PROFESÖR SEDAT ABUŞOĞLU →
Makale Bilgileri
DergiJournal of Pharmaceutical and Biomedical Analysis
Yayın TarihiŞubat 2020
Cilt / Sayfa180
Scopus ID2-s2.0-85076920327
Özet
Objective: Clozapine is one of the most effective drugs for resistant schizophrenia, but its severe metabolic and hematological side effects limit the use of clozapine. It has been reported that clozapine blood concentrations should be maintained between 350−600 ng/mL. Our aim was to develop a determination method for clozapine and its main metabolites norclozapine and clozapine-N-oxide, to perform validation studies and to investigate the change of various biochemical parameters in patients using clozapine. Methods: A liquid chromatography-tandem mass spectrometry (LC–MS/MS) method was developed and validated for clozapine measurement. Thus, blood samples were collected from 38 patients with schizophrenia and 32 healthy volunteers. Biochemical and hematological parameters were measured by Beckman-Coulter AU 5800 (Beckman Coulter, Brea, USA) and Beckman Coulter LH 780 analyzer (Beckman Coulter, Miami, FL, USA), respectively. Hormone levels were analyzed using Cobas 6000 analyzer (Roche Diagnostics, Germany). Results: The LC[sbnd]MS/MS method was linear between 1.22−2500 ng/mL (r2 = 0.9971) for clozapine. The retention times of clozapine, norclozapine and clozapine-N-oxide were 0.92, 0.89 and 0.95, respectively. Blood glucose (GLU) (p = 0.025), low density lipoprotein (LDL-cholesterol) (p = 0.015), triglyseride (TG) (p = 0.042) and total cholesterol (TC) (p = 0.024) levels were higher; hemoglobin (HGB) (0.015), mean corpuscular hemoglobin (MCH) (0.036), red blood cell count (RBC) (0.020), neutrophil (NEU) (0.034), and platelet (PLT) (P = 0.005) levels were lower in the clozapine group. Conclusions: This LC–MS/MS method was rapid, simple, cost-effective and suitable for the routine clozapine monitoring. Furthermore, norclozapine and clozapine-N-oxide were also determined. Monitoring of metabolic and hematological parameters with clozapine levels is very important. However, the limitations of the study were that the method was not validated for norclozapine and clozapine-N-oxide, so the validation parameters were not evaluated for these two metabolites.
Yazarlar (8)
1
Karam Mazin Kamil Gharab
2
Duygu Eryavuz Onmaz
ORCID: 0000-0001-8564-1824
3
Sedat Abusoglu
ORCID: 0000-0002-2984-0527
4
Memduha Aydin
5
Abdullah Sivrikaya
6
Oguzhan Tok
7
Gulsum Abusoglu
8
Ali Ünlü
ORCID: 0000-0002-9991-3939
Anahtar Kelimeler
Clozapine
Side effects
Tandem mass spectrometry
Therapeutic drug monitoring
Kurumlar
Selçuk Üniversitesi
Selçuklu Turkey
Metrikler
6
Atıf
8
Yazar
4
Anahtar Kelime